Trochanteric Fractures
13
0
3
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
7.7%
1 terminated out of 13 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (13)
G7 Freedom Constrained Vivacit-E Liners
ZNN Bactiguard Cephalomedullary Nails PMCF Study
G7 BiSpherical Acetabular Shell PMCF Study
G7 Dual Mobility With Vivacit-E or Longevity PMCF
Insignia™ Hip Stem Outcomes Study
Post-market Surveillance Study With the HYPERION Hip Endoprosthesis System in Defect Reconstruction
Treatment Of Unstable Trochanteric Fracture: A Comparative Study Between DHS And DHS With Trochanteric Stabilization Plate
PFNA vs Dual Mobility in Treatment of Unstable Trochanteric Fractures
Treatment of Unstable Trochanteric Fractures With the Proximal Femoral Nail - Antirotation (PFNA)-Asia
Trochanteric Hip Fractures (AO A2) SHS With or Without Trochanteric Stabilizing Plate - Rct Using RSA
Results of Gamma Nail in Trochentric Fractures of the Adults
Interest of Navigation for the Treatment of Pertrochanteric Fractures With the Gamma 3 Nail
Effect of PTH(1-34) Treatment on Fracture Healing in Vivo